Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

The letter specifies violations at its Halol facility, with regards to manufacturing of goods.

FPJ Web DeskUpdated: Friday, December 16, 2022, 07:35 PM IST
article-image
Representational image |

Through an exchange filing, Revital maker Sun Pharma has informed that it has received a warning letter from the US Food and Drug Administration.

The letter specifies violations at its Halol facility, with regards to manufacturing of goods, and contents of the letter will be released to the public soon.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

GameChangers 2022: Shashi Sinha, IPG Mediabrands – Giving back to the industry is what keeps me...

GameChangers 2022: Shashi Sinha, IPG Mediabrands – Giving back to the industry is what keeps me...

Airlines will be asked to cap airfares on routes affected by Go First crisis, says Civil Aviation...

Airlines will be asked to cap airfares on routes affected by Go First crisis, says Civil Aviation...

Bids worth ₹6,500 crore pour in for government's stake sale in Coal India

Bids worth ₹6,500 crore pour in for government's stake sale in Coal India

PharmEasy's investor slashes its valuation days after Byju's markdown

PharmEasy's investor slashes its valuation days after Byju's markdown

Check out ways to get discounts on insurance policies by staying fit

Check out ways to get discounts on insurance policies by staying fit